| Study groups | P value | |
---|---|---|---|
esSCLC | mNSCLC | ||
(N = 5,855) | (N = 24,090) | ||
Post-index prevalence of cancer-directed therapies | Â | Â | Â |
 Overall, n (%)a |  |  |  |
  Surgery | 458 (7.8) | 3,278 (13.6) | < 0.001 |
  Radiation therapy | 3,827 (65.4) | 18,208 (75.6) | < 0.001 |
  Biologic therapy | 103 (1.8) | 282 (1.2) | < 0.001 |
  Chemotherapy | 5,003 (85.4) | 14,527 (60.3) | < 0.001 |
    No. cycles received in first-line treatment, mean (SD) | 3.4 (2.1) | 3.2 (2.3) |  |
Post-index prevalence of supportive or palliative therapies | Â | Â | Â |
 Growth factors, n (%)a |  |  |  |
  Filgrastim/pegfilgrastim/sargramostim | 2,483 (42.4) | 4,275 (17.8) | < 0.001 |
  Darbepoetin/erythropoietin | 2,926 (50.0) | 8,640 (35.9) | < 0.001 |
  Any growth factor | 3,453 (59.0) | 9,506 (39.5) | < 0.001 |
 Other supportive or palliative therapies, n (%)a |  |  |  |
  Iron supplements | 39 (0.7) | 249 (1.0) | 0.012 |
  Antibiotics | 613 (10.5) | 2,328 (9.7) | 0.063 |
  Antiemetics | 4,095 (69.9) | 12,947 (53.7) | < 0.001 |
  Antifungalsb |  | 21 (0.1) |  |
  Pain medications | 1,366 (23.3) | 5,782 (24.0) | 0.280 |
  Bisphosphonates | 373 (6.4) | 2,271 (9.4) | < 0.001 |
  Megestrol acetate | 2,276 (38.9) | 6,078 (25.2) | < 0.001 |
  Oxygen | 1,696 (29.0) | 6,861 (28.5) | 0.118 |
  Red blood-cell transfusion | 1,212 (20.7) | 2,629 (10.9) | < 0.001 |
  Platelet transfusion | 330 (5.6) | 426 (1.8) | < 0.001 |